Investigate Vaccine Formulations with HIV Immunogens and Adjuvants

Funding News Edition: March 01, 2023
See more articles in this edition

Through the new broad agency announcement (BAA) Rational Systematic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA), NIAID is soliciting contract proposals from offerors capable of providing a broad range of services to investigate vaccine formulations with HIV immunogens and adjuvants.

The R-CASA program will complement and expand NIAID’s Adjuvant Comparison and Characterization program by:

  • Expanding the number of HIV immunogens that can be investigated for eliciting broad neutralizing antibodies as well as relevant T cell responses.
  • Expanding the number of clinically relevant adjuvants that can be investigated.
  • Investigating the effects of alternative immunization strategies and regimens (e.g., escalating dosing, viral vectors, immunogens).

Successful offerors will develop new approaches to assess optimal HIV immunogens-adjuvants formulations prior to transitions into clinical trials. Thus, offerors should propose to:

  1. Generate and propose standardized protocols and endpoint assays for rational and systematic down-screening of HIV immunogen-adjuvant formulations.
  2. Apply those protocols and assays to screen HIV immunogen-adjuvant formulations.
  3. Screen additional immunogens and adjuvants at the direction of NIAID.

In combination, these efforts will delineate a standardized set of assays for biochemical and immunological characterization of HIV immunogen-adjuvant formulations, down-selection workflow, and go, no-go criteria to maximize successful transitions of immunogen-adjuvant formulations from preclinical testing to First-in-Humans trials.

Your proposal should explain how you will contribute to the objectives described above. Contracts awarded through this BAA will include a statement of work proposed by you as the offeror and then negotiated and accepted by the government. Review the R-CASA BAA linked above for a complete list of research and technical objectives, as well as the corresponding technical evaluation criteria.

NIAID estimates making one or two awards, each with $2 million average annual total costs. The proposed period of performance should reflect the complexity of the proposed research, but not exceed 5 years.

The deadline to submit an offer is June 21, 2023, at 4 p.m. Eastern Time.

If you have any questions about the BAA, contact Kishan Patel, NIAID contracting officer, at or 301-451-4334.

Contact Us

Email us at for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on